AI-Powered Summary

Market Context

Top Queries

More News

Explore Prysm Tools

Related Stories

Kilitch Drugs (India) Ltd. Q3 FY26 Certificate Under SEBI Regulation 74(5)

Kilitch Drugs (India) Limited

AI Sentiment Analysis

January 15, 2026, 06:17 AM

Kilitch Drugs (India) Limited received a certificate from its RTA, MUFG Intime India Private Limited, for the quarter ended December 31, 2025. This confirms compliance with SEBI (Depositories and Participants) Regulations, 2018, regarding the dematerialisation of securities.

Top Queries to Ask About Kilitch Drugs (India) Limited

Thinking to buy or sell Kilitch Drugs (India) Limited? Ask AI before you act.

Users

Trusted by 5,000+ users

More Details on This News

Kilitch Drugs (India) Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate pertains to the quarter ended December 31, 2025.

The company received this confirmation from MUFG Intime India Private Limited, its Registrar and Share Transfer Agent. The certificate confirms that the securities received from depository participants for dematerialisation during the specified quarter were processed, and the security certificates were duly mutilated, cancelled, and replaced with depository entries in the register of members within the stipulated timelines.

This is a routine compliance filing to ensure proper record-keeping and adherence to SEBI regulations regarding the dematerialisation of securities.

More News on Kilitch Drugs (India) Limited

Analyze Kilitch Drugs (India) Limited

Discover more trending news on Prysm

View All